Prognostic impact of activation-induced cytidine deaminase expression for patients with diffuse large B-cell lymphoma

References

• Muramatsu M, Kinoshita K, Fagarasan S, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102:553–563.
   PubMed Web of Science ®Google Scholar
• Revy P, Muto T, Levy Y, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell. 2000;102:565–575.
   PubMed Web of Science ®Google Scholar
• Martin A, Bardwell PD, Woo CJ, et al. Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas. Nature. 2002;415:802–806.
   PubMed Web of Science ®Google Scholar
• Muramatsu M, Sankaranand V, Anant S, et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem. 1999;274:18470–18476.
   PubMed Web of Science ®Google Scholar
• Küppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20:5580–5594.
   PubMed Web of Science ®Google Scholar
• Okazaki I-m, Kotani A, Honjo T. Role of AID in tumorigenesis. Adv Immunol. 2007;94:245–273.
   PubMedGoogle Scholar
• Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341–346.
   PubMed Web of Science ®Google Scholar
• Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012;109:3879–3884.
   PubMed Web of Science ®Google Scholar
• Hardianti MS, Tatsumi E, Syampurnawati M, et al. Activation-induced cytidine deaminase expression in follicular lymphoma: association between AID expression and ongoing mutation in FL. Leukemia. 2004;18:826–831.
   PubMed Web of Science ®Google Scholar
• Shikata H, Yakushijin Y, Matsushita N, et al. Role of activation-induced cytidine deaminase in the progression of follicular lymphoma. Cancer Sci. 2012;103:415–421.
   PubMed Web of Science ®Google Scholar
• Deutsch AJ, Aigelsreiter A, Staber PB, et al. MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. Blood. 2007;109:3500–3504.
   PubMed Web of Science ®Google Scholar
• McCarthy H, Wierda WG, Barron LL, et al. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood. 2003;101:4903–4908.
   PubMed Web of Science ®Google Scholar
• Reiniger L, Bödör C, Bognar A, et al. Richter's and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation. Leukemia. 2006;20:1089–1095.
   PubMed Web of Science ®Google Scholar
• Greeve J, Philipsen A, Krause K, et al. Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas. Blood. 2003;101:3574–3580.
   PubMed Web of Science ®Google Scholar
• Smit LA, Bende RJ, Aten J, et al. Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal-center phenotype. Cancer Res. 2003;63:3894–3898.
   PubMed Web of Science ®Google Scholar
• Lossos I, Levy R, Alizadeh A. AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity. Leukemia. 2004;18:1775–1779.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Guglielmino R, Houldsworth J, et al. Expression of the AID protein in normal and neoplastic B cells. Blood. 2004;104:3318–3325.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica. 2008;93:1829–1836.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684–3688.
   PubMed Web of Science ®Google Scholar
• Okamoto M, Maruyama F, Tsuzuki M, et al. Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin. Jpn J Clin Hematol. 1994;35:635–641.
   PubMedGoogle Scholar
• Oki Y, Ogura M, Kato H, et al. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Sci. 2008;99:179–184.
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Yoshizawa A, Sumiyoshi S, et al. Adipophilin expression in lung adenocarcinoma is associated with an apocrine-like features and poor clinical prognosis: an immunohistochemical study of 328 cases. Histopathology. 2017;70:232–241.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170.
   PubMedGoogle Scholar
• Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J Roy Stat Soc A. 1972;135:185–207.
   Web of Science ®Google Scholar
• Prentice RL. Linear rank tests with right censored data. Biometrika. 1978;65:167–179.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables. J Roy Stat Soc B Stat Meth. 1972;34:187–220.
   Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452–458.
   PubMed Web of Science ®Google Scholar
• Sciammas R, Shaffer A, Schatz JH, et al. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity. 2006;25:225–236.
   PubMed Web of Science ®Google Scholar
• Lenz G, Nagel I, Siebert R, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med. 2007;204:633–643.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Kawamura K, Wada A, Wang J-Y, et al. Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy. J Cancer Res Clin Oncol. 2016;142:27–36.
   PubMed Web of Science ®Google Scholar
• Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100:9991–9996.
   PubMed Web of Science ®Google Scholar
• De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat Rev Immunol. 2015;15:137–148.
   PubMed Web of Science ®Google Scholar
• Meyer PN, Fu K, Greiner TC, et al. Immunohisto-chemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2010;29:200–207.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non–germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol. 2014;33:251–257.
   PubMed Web of Science ®Google Scholar
• Younes A, Thieblemont C, Morschhauser F, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014;15:1019–1026.
   PubMed Web of Science ®Google Scholar
• Cattoretti G, Büttner M, Shaknovich R, et al. Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells. Blood. 2006;107:3967–3975.
   PubMed Web of Science ®Google Scholar